Path Grand Rounds: Dr. Deepti Reddi

This event has ended.

Speaker

Deepti Reddi, MD
Acting Assistant Professor
Department of Pathology
University of Washington


Date & Time

February 5, 2020 at 1:30pm - 2:30pm

Location

UWMC NE110K

Calendar

Path Grand Rounds

Export
Add to Calendar 02/05/2020 01:30 PM 02/05/2020 02:30 PM America/Los_Angeles Path Grand Rounds: Dr. Deepti Reddi Path Grand Rounds: Dr. Deepti Reddi

Deepti Reddi, MD
Acting Assistant Professor
Department of Pathology
University of Washington
"Whats New in Colon Cancer"   In the United States, cancer is the second leading cause of death and it is estimated that there will be 328,030 new cancer cases of the digestive system in 2019. The rising incidence of colorectal carcinoma in younger individuals has prompted American Cancer Society to revise their guidelines in 2018 to initiate screening at the age of 45 years in average risk individuals. Since the publication of the fourth-edition of WHO Classification of Digestive System Tumors in 2010, there have been recent advancements in our understanding of tumor types based on molecular pathology. Even though the gold standard for diagnosis is by histopathological classifications, certain tumor types are being defined by molecular phenotype. In addition, molecular markers are used to predict tumor prognosis and dictate therapy.
UWMC NE110K false MM/DD/YYYY

Description

"Whats New in Colon Cancer"

 

In the United States, cancer is the second leading cause of death and it is estimated that there will be 328,030 new cancer cases of the digestive system in 2019. The rising incidence of colorectal carcinoma in younger individuals has prompted American Cancer Society to revise their guidelines in 2018 to initiate screening at the age of 45 years in average risk individuals. Since the publication of the fourth-edition of WHO Classification of Digestive System Tumors in 2010, there have been recent advancements in our understanding of tumor types based on molecular pathology. Even though the gold standard for diagnosis is by histopathological classifications, certain tumor types are being defined by molecular phenotype. In addition, molecular markers are used to predict tumor prognosis and dictate therapy.

File Attachments